MedTrace Logo

89Zr-labeled NY009 PET Imaging in Patients

NCT05691855 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-01-20

No results posted yet for this study

Summary

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY009 PET Imaging in patients

Conditions

Interventions

DRUG

89Zr-NY009

Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    lead OTHER

Principal Investigators

  • Chunjing Yu · Affiliated Hospital of Jiangnan University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05691855 on ClinicalTrials.gov